ERBB2 and breast carcinoma: Although the effect of MALAT1 silencing in TNBC and Her-2 positive breast cancer remains to be further verified in animal models, the results of above-mentioned experiments would pave the way for breast cancer clinical trials of MALAT1 in molecular targeted therapies.